{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.6","upperLimit":"49.1","value":"34.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Adverse events are graded using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) v2.0. Grade refers to the severity of the toxicity by assigning Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to toxicity. \"Acute\" refers to toxicities occurring less than or equal to 90 days from the start of radiation therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes followed by post-operative radiation therapy.","id":"OG000","title":"Surgery + Transfer + Radiation"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started RT","reportingStatus":"POSTED","timeFrame":"From start of radiation therapy to 90 days","title":"Percentage of Patients Experiencing Acute Grade 3-4 Toxicity Definitely, Probably, or Possibly Related to Radiation Therapy or Chemotherapy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}